-
公开(公告)号:US08148322B2
公开(公告)日:2012-04-03
申请号:US12631048
申请日:2009-12-04
申请人: Hazel Szeto , Kesheng Zhao , Hugh Robertson , Alex Birk
发明人: Hazel Szeto , Kesheng Zhao , Hugh Robertson , Alex Birk
IPC分类号: A61K38/07
CPC分类号: A61K47/48246 , A61K31/713 , A61K38/47 , A61K47/64 , A61K47/645 , C07K5/1016 , C07K5/1019 , C07K17/00 , C12N9/2471 , C12N9/96 , C12N15/113 , C12N15/87 , C12N2310/3513 , C12N2320/32 , C12Y302/01023
摘要: The invention relates to carrier complexes and methods for delivering molecules to cells. The carrier complexes comprises a molecule and an aromatic cationic peptide in accordance with the invention. In one embodiment, the method for delivering a molecule to a cell comprises contacting the cell with a carrier complex. In another embodiment, the method for delivering a molecule to a cell comprises contacting the cell with a molecule and an aromatic cationic peptide.
摘要翻译: 本发明涉及用于将分子递送至细胞的载体复合物和方法。 载体复合物包含根据本发明的分子和芳族阳离子肽。 在一个实施方案中,将分子递送至细胞的方法包括使细胞与载体复合物接触。 在另一个实施方案中,将分子递送至细胞的方法包括使细胞与分子和芳族阳离子肽接触。
-
公开(公告)号:US20050158373A1
公开(公告)日:2005-07-21
申请号:US10838135
申请日:2004-05-03
申请人: Hazel Szeto , Kesheng Zhao , Hugh Robertson , Alex Birk
发明人: Hazel Szeto , Kesheng Zhao , Hugh Robertson , Alex Birk
IPC分类号: A61K9/127 , A61K47/48 , A61K48/00 , C07K5/00 , C07K5/107 , C07K5/11 , C12N20060101 , C12N15/85 , C12N15/87
CPC分类号: A61K47/48246 , A61K31/713 , A61K38/47 , A61K47/64 , A61K47/645 , C07K5/1016 , C07K5/1019 , C07K17/00 , C12N9/2471 , C12N9/96 , C12N15/113 , C12N15/87 , C12N2310/3513 , C12N2320/32 , C12Y302/01023
摘要: The invention relates to carrier complexes and methods for delivering molecules to cells. The carrier complexes comprises a molecule and an aromatic cationic peptide in accordance with the invention. In one embodiment, the method for delivering a molecule to a cell comprises contacting the cell with a carrier complex. In another embodiment, the method for delivering a molecule to a cell comprises contacting the cell with a molecule and an aromatic cationic peptide.
摘要翻译: 本发明涉及用于将分子递送至细胞的载体复合物和方法。 载体复合物包含根据本发明的分子和芳族阳离子肽。 在一个实施方案中,将分子递送至细胞的方法包括使细胞与载体复合物接触。 在另一个实施方案中,将分子递送至细胞的方法包括使细胞与分子和芳族阳离子肽接触。
-
公开(公告)号:US09315586B2
公开(公告)日:2016-04-19
申请号:US13422722
申请日:2012-03-16
申请人: Hazel Szeto , Kesheng Zhao , Hugh Robertson , Alex V. Birk
发明人: Hazel Szeto , Kesheng Zhao , Hugh Robertson , Alex V. Birk
CPC分类号: A61K47/48246 , A61K31/713 , A61K38/47 , A61K47/64 , A61K47/645 , C07K5/1016 , C07K5/1019 , C07K17/00 , C12N9/2471 , C12N9/96 , C12N15/113 , C12N15/87 , C12N2310/3513 , C12N2320/32 , C12Y302/01023
摘要: The invention relates to carrier complexes and methods for delivering molecules to cells. The carrier complexes comprises a molecule and an aromatic cationic peptide in accordance with the invention. In one embodiment, the method for delivering a molecule to a cell comprises contacting the cell with a carrier complex. In another embodiment, the method for delivering a molecule to a cell comprises contacting the cell with a molecule and an aromatic cationic peptide.
摘要翻译: 本发明涉及用于将分子递送至细胞的载体复合物和方法。 载体复合物包含根据本发明的分子和芳族阳离子肽。 在一个实施方案中,将分子递送至细胞的方法包括使细胞与载体复合物接触。 在另一个实施方案中,将分子递送至细胞的方法包括使细胞与分子和芳族阳离子肽接触。
-
公开(公告)号:US20070027087A1
公开(公告)日:2007-02-01
申请号:US11427804
申请日:2006-06-30
申请人: Hazel Szeto , Kesheng Zhao , Peter Schiller
发明人: Hazel Szeto , Kesheng Zhao , Peter Schiller
CPC分类号: A61K38/07 , A61K38/03 , C07K5/1008 , C07K5/1016 , C07K5/1019 , C07K5/1024
摘要: The invention provides a method of reducing or preventing mitochondrial permeability transitioning. The method comprises administering an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3pm is the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 2 a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1.
摘要翻译: 本发明提供了减少或预防线粒体渗透性转换的方法。 该方法包括施用有效量的具有至少一个净正电荷的芳族阳离子肽; 至少四个氨基酸; 最多约20个氨基酸; 净正电荷的最小数量(p
t)之间的关系,其中2 a是小于或等于p < t + 1,除了当a为1时,p 也可以为1。 -
公开(公告)号:US08618061B2
公开(公告)日:2013-12-31
申请号:US12843333
申请日:2010-07-26
申请人: Hazel Szeto
发明人: Hazel Szeto
IPC分类号: A61K38/07
CPC分类号: A61K38/07 , A61K38/08 , A61K38/10 , C07K5/1019
摘要: The invention provides a method for reducing oxidative damage in a mammal, a removed organ, or a cell in need thereof. The method comprises administering an effective amount of an aromatic cationic peptide. The aromatic cationic peptide has (a) at least one net positive charge; (b) a minimum of three amino acids; (c) a maximum of about twenty amino acids, (d) a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3 pm is the largest number that is less than or equal to r+1; (e) a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 3a or 2a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1; and (f) at least one tyrosine or tryptophan amino acid.
摘要翻译: 本发明提供了一种减少哺乳动物,被去除的器官或有需要的细胞的氧化损伤的方法。 该方法包括施用有效量的芳族阳离子肽。 芳族阳离子肽具有(a)至少一个净正电荷; (b)至少三个氨基酸; (c)最多约20个氨基酸,(d)最小净正电荷数(pm)与氨基酸残基总数(r)之间的关系,其中3pm是最小数目小于或等于 等于r + 1; (e)芳族基团(a)的最小数目和净正电荷总数(pt)之间的关系,其中3a或2a是小于或等于pt + 1的最大数,除了当a为 1,pt也可以为1; 和(f)至少一种酪氨酸或色氨酸氨基酸。
-
公开(公告)号:US07732398B2
公开(公告)日:2010-06-08
申请号:US11427606
申请日:2006-06-29
申请人: Hazel Szeto , Peter W. Schiller
发明人: Hazel Szeto , Peter W. Schiller
摘要: The present invention provides methods for stimulating mu-opioid receptors with agonist peptides in a mammal in need thereof. The methods comprise administering to the mammal an effective amount of a selective mu-opioid receptor agonist peptide that comprises at least two α-amino acid residues. At least one of the amino acid residues has a positive charge. The amino acid residue in the first position is a tyrosine or tyrosine derivative. The amino acid in the second position is a D-α-amino acid. The present invention also provides methods of treating a mammal suffering from conditions or diseases by administering to the mammal an effective amount of the peptides.
摘要翻译: 本发明提供了在有需要的哺乳动物中用激动剂肽刺激μ-阿片受体的方法。 所述方法包括向哺乳动物施用有效量的包含至少两个α-氨基酸残基的选择性μ-阿片受体激动剂肽。 至少一个氨基酸残基具有正电荷。 第一位置的氨基酸残基是酪氨酸或酪氨酸衍生物。 第二个位置的氨基酸是D-α-氨基酸。 本发明还提供了通过向哺乳动物施用有效量的肽来治疗患有病症或疾病的哺乳动物的方法。
-
公开(公告)号:US20060084606A1
公开(公告)日:2006-04-20
申请号:US11040242
申请日:2005-01-21
申请人: Hazel Szeto
发明人: Hazel Szeto
CPC分类号: A61K38/07 , A61K38/08 , A61K38/10 , C07K5/1019
摘要: The invention provides a method for reducing oxidative damage in a mammal, a removed organ, or a cell in need thereof. The method comprises administering an effective amount of an aromatic cationic peptide. The aromatic cationic peptide has (a) at least one net positive charge; (b) a minimum of three amino acids; (c) a maximum of about twenty amino acids; (d) a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3pm is the largest number that is less than or equal to r+1; (e) a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 3a or 2a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1; and (f) at least one tyrosine or tryptophan amino acid.
摘要翻译: 本发明提供了一种减少哺乳动物,被去除的器官或有需要的细胞的氧化损伤的方法。 该方法包括施用有效量的芳族阳离子肽。 芳族阳离子肽具有(a)至少一个净正电荷; (b)至少三个氨基酸; (c)最多约20个氨基酸; (d)最小净正电荷数(p
和氨基酸残基总数(r)之间的关系,其中3pm m是最大数量, 小于或等于r + 1; (e)芳族基团(a)的最小数目和净正电荷总数(pt)之间的关系,其中3a或2a是小于或等于p < +1,除了当a为1时,p 也可以为1; 和(f)至少一种酪氨酸或色氨酸氨基酸。 -
公开(公告)号:US07498297B2
公开(公告)日:2009-03-03
申请号:US10333485
申请日:2001-07-18
申请人: Hazel Szeto , Peter W. Schiller
发明人: Hazel Szeto , Peter W. Schiller
摘要: The present invention provides methods for stimulating a mu-opioid receptor agonist peptide in a mammal in need thereof. The methods comprise administering to the mammal an effective amount of a selective mu-opioid receptor agonist peptide that comprises at least two α-amino acid residues. At least one of the amino acid residues has a positive charge. The amino acid residue in the first position is a tyrosine or tyrosine derivative. The amino acid in the second position is a D-α-amino acid. The present invention also provides methods of treating a mammal suffering from conditions or diseases by administering to the mammal an effective amount of the peptides.
摘要翻译: 本发明提供了在有需要的哺乳动物中刺激μ-阿片受体激动剂肽的方法。 所述方法包括向哺乳动物施用有效量的包含至少两个α-氨基酸残基的选择性μ-阿片受体激动剂肽。 至少一个氨基酸残基具有正电荷。 第一位置的氨基酸残基是酪氨酸或酪氨酸衍生物。 第二个位置的氨基酸是D-α-氨基酸。 本发明还提供了通过向哺乳动物施用有效量的肽来治疗患有病症或疾病的哺乳动物的方法。
-
公开(公告)号:US20070129306A1
公开(公告)日:2007-06-07
申请号:US11532764
申请日:2006-09-18
申请人: Hazel Szeto , Shaoyi Liu , Sunghee Cho
发明人: Hazel Szeto , Shaoyi Liu , Sunghee Cho
CPC分类号: C07K5/101 , A61K38/00 , A61K38/03 , A61K38/06 , A61K38/08 , C07K5/1008 , C07K5/1016 , C07K5/1019 , C07K5/1024 , C07K14/705
摘要: The invention provides a method of reducing CD36 expression in a cell. The method comprises contacting the cell with an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3pm is the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 2a is the largest number that is less than or equal to pt−1, except that when a is 1, pt may also be 1.
摘要翻译: 本发明提供减少细胞中CD36表达的方法。 该方法包括使细胞与有效量的具有至少一个净正电荷的芳族阳离子肽接触; 至少四个氨基酸; 最多约20个氨基酸; 净正电荷的最小数量(p
t)之间的关系,其中2a是小于或等于p T的最大数目 SUB> -1,除了当a是1时,p 也可以是1。 -
公开(公告)号:US20070027070A1
公开(公告)日:2007-02-01
申请号:US11427606
申请日:2006-06-29
申请人: Hazel Szeto , Peter Schiller
发明人: Hazel Szeto , Peter Schiller
摘要: The present invention provides methods for stimulating mu-opioid receptors with agonist peptides in a mammal in need thereof. The methods comprise administering to the mammal an effective amount of a selective mu-opioid receptor agonist peptide that comprises at least two α-amino acid residues. At least one of the amino acid residues has a positive charge. The amino acid residue in the first position is a tyrosine or tyrosine derivative. The amino acid in the second position is a D-α-amino acid. The present invention also provides methods of treating a mammal suffering from conditions or diseases by administering to the mammal an effective amount of the peptides.
摘要翻译: 本发明提供了在有需要的哺乳动物中用激动剂肽刺激μ-阿片受体的方法。 所述方法包括向哺乳动物施用有效量的包含至少两个α-氨基酸残基的选择性μ-阿片受体激动剂肽。 至少一个氨基酸残基具有正电荷。 第一位置的氨基酸残基是酪氨酸或酪氨酸衍生物。 第二个位置的氨基酸是D-α-氨基酸。 本发明还提供了通过向哺乳动物施用有效量的肽来治疗患有病症或疾病的哺乳动物的方法。
-
-
-
-
-
-
-
-
-